DTRX Stock UPDATES Detrex Cp (DTRX) 35.5000 08/03/2014 06:24

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Detrex Cp (DTRX) 35.5000 $DTRX

Detrex Corporation Reports Earnings for the Second Quarter of 2014 and Announces a Third Quarter Dividend
Business Wire - Thu Jul 24, 9:39AM CDT
Detrex Corporation (OTCQX TRX), today announced 2014 second quarter net income from continuing operations of $521,140, or $0.30 per fully diluted share, compared to net income of $914,499 or $0.52 per fully diluted share, in the second quarter of 2013. Year-to-date 2014 net income from continuing operations was $1,063,085, or $0.61 per fully diluted share. This compares to 2013 year-to-date net income of $1,953,152, or $1.13 per fully diluted share. In the second quarter of 2014 the Company settled a dispute with the buyer of the Harvel Plastics, Inc. business in order to collect the escrow related to the transaction. The net income charge for the settlement and associated legal costs was $304,139. This amount is reflected in discontinued operations and second quarter net income after discontinued operations is $217,001, or $0.12 per fully diluted share, and on a year-to-date basis is $758,946, or $0.43 per fully diluted share. The Company also announced that it will pay a $0.25 quarterly dividend on September 17, 2014 to shareholders of record as of September 3, 2014.

Detrex reports reduced net income for FY 2013 year over year and Q1 dividend of USD0.25 per share
M2 - Mon Mar 03, 5:42AM CST
Detrex Corporation (OTCQX TRX), the holding company of a manufacturer of specialty chemicals, reported on Friday net income of USD2.6m or USD1.51 per fully diluted share, compared to the total net income of USD7.7m or USD4.49 per fully diluted share in 2012 that included the gain on the sale of Harvel Plastics Inc.

Detrex Corporation Announces Earnings for Full Year 2013 and Announces a First Quarter Dividend
Business Wire - Fri Feb 28, 9:22AM CST
Detrex Corporation (OTCQX TRX), today announced 2013 full year net income of $2.6 million, or $1.51 per fully diluted share, on sales of $41.0 million. In 2012 net sales were $43.4 million and the Company generated a net loss from continuing operations of $7 million inclusive of pre-tax environmental charges of $15.7 million. The total net income in 2012, including the gain on the sale of Harvel Plastics, Inc., was $7.7 million, or $4.49 per fully diluted share. The Company also announced that it will pay a $0.25 quarterly dividend on March 27, 2014 to shareholders of record as of March 13, 2014.

Detrex signs contract to transfer environmental liabilities with ELT for USD13.7m
M2 - Wed Jun 19, 3:10AM CDT
A chemical company, Detrex Corporation (DTRX.PK) revealed on Tuesday that it signed a contract with Environmental Liability Transfer Inc (ELT) to transfer environmental liabilities and obligations related to 20 properties, for a payment of about USD13.7m.

Detrex Corporation Announces the Signing of an Environmental Liability Transfer Contract
Business Wire - Tue Jun 18, 2:26PM CDT
Detrex Corporation (DTRX.PK) announced that effective today it closed on a contract to transfer environmental liabilities and obligations associated with 20 properties to Environmental Liability Transfer, Inc. ("ELT" for a payment of approximately $13.7 million. The contract also transferred title to four properties owned by Detrex. In conjunction with the contract, the Company also purchased a pollution legal liability policy (PLL) which provides coverage for third party liability. This transaction is explained in greater detail under Note 15 - Subsequent Event contained in the Detrex 2012 Annual Report on page 28.

Detrex Corporation Reports Earnings for the First Quarter of 2013 and Announces a 2nd Quarter Dividend
Business Wire - Tue Apr 30, 8:18AM CDT
Detrex Corporation (Pink Sheets: DTRX), today announced 2013 first quarter net income from continuing operations of $1,038,653, or $0.60 per fully diluted share, compared to 2012 net income from continuing operations of $726,254, or $0.42 per fully diluted share. The 2012 net income of $17,671,979, or $10.34 per fully diluted share included income from discontinued operations of $16,945,725, or $9.92 per fully diluted share, from the gain on the sale of the Harvel Plastics, Inc. subsidiary. The Company also announced that it will pay a second quarter dividend of $0.25 per share on June 27, 2013 to shareholders of record on June 17, 2013.

Detrex Corporation Announces Earnings for Full Year 2012 and the Signing of a Non-binding Letter of Intent for an Environmental Liability Transfer
Business Wire - Thu Apr 25, 8:51AM CDT
Detrex Corporation (Pink Sheets: DTRX) , today announced 2012 full year net income of $7.7 million, or $4.49 per fully diluted share, compared to $4.3 million, or $2.53 per fully diluted share, in 2011. The Company also announced the signing of a non-binding letter of intent to enter into a transaction to transfer a significant portion of its environmental liabilities to a third party.

Detrex Corporation Board of Directors Authorizes a 1st Quarter Dividend
Business Wire - Tue Mar 05, 10:57AM CST
Detrex Corporation (Pink Sheets: DTRX) announced today that it will pay a $0.25 quarterly dividend on March 28, 2013 to shareholders of record as of March 15, 2013.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 59

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 80

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 299

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 242

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading